Aditxt Inc. (NASDAQ: ADTX) May Be Down From Monday's Alert Price, But History Shows What Comes Next!
Published: Wed, 02/26/25
Updated: Wed, 02/26/25
Get the Full Story - Breaking News Released! Download our Mobile App📱
SPONSORED
.
Aditxt Inc. (NASDAQ: ADTX) May Be Down From Monday's Alert Price, But History Shows What Comes Next!
Aditxt Inc.
(NASDAQ: $ADTX)
===========================
Alert Price - $0.0872 per share
Current Price - $0.0759 (-12.95%)
Market Cap - $5.998M
Avg. Volume - $68,403,917
Members,
Short-term pullbacks are common before major breakouts,
and Aditxt Inc. (NASDAQ: ADTX) is no exception. While the stock has dipped 12% from our initial alert at $0.0872 to $0.0759, the broader setup remains intact. Historical patterns suggest that such consolidations often precede explosive moves. With $ADTX still trading within a falling wedge and RSI at 19, the stage is set for a potential massive rebound.
We believe NASDAQ: ADTX is on the brink of a potential game-changing breakout that could deliver a staggering 3,000% surge, presenting a massive short-term opportunity while holding long-term potential as a leader in the biotech space.
About Aditxt Inc. (NASDAQ: ADTX)
Aditxt Inc. (NASDAQ: ADTX), a cutting-edge biotechnology company
founded in 2017 and headquartered in Richmond, Virginia, is revolutionizing immune system monitoring and modulation through its groundbreaking technologies aimed at improving health outcomes. Operating within the healthcare sector, Aditxt specializes in developing and commercializing innovative solutions such as AditxtScore, a pioneering platform designed to help individuals understand, manage, and monitor their immune profiles, offering critical insights into immune responses and potential
threats.
Additionally, the company is advancing Apoptotic DNA Immunotherapy (ADI), a nucleic acid-based technology that mimics the body’s natural tolerance mechanisms, presenting a novel approach to treating autoimmune diseases and preventing organ transplant rejection. Aditxt’s expanding pipeline includes ADI-100, a
promising candidate targeting conditions such as skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis.
With exclusive licensing agreements with prestigious institutions like Loma Linda University and Leland Stanford Junior University, Aditxt is positioned at the forefront of biotech innovation. The company went public on June 30, 2020, and was originally known as ADiTx Therapeutics, Inc. before rebranding to Aditxt Inc. in July 2021. With a strong focus on
immune system health and a growing presence in the biotech sector, Aditxt Inc. continues to drive advancements that could reshape the future of immunotherapy and precision medicine.
Amro Albanna, Co-Founder, Chairman and CEO of Aditxt Commented:
“Cancer is one of the most pressing health challenges, and early detection is key to the fight against cancer, Pearsanta’s planned IPO reflects Aditxt’s business model of identifying, developing and launching promising innovative solutions that drive medical advancements, improve healthcare accessibility and address critical unmet needs. We believe that this milestone is a critical step in Pearsanta’s path to
commercialization, expanding its potential beyond oncology to a broader range of diseases where early intervention can have a meaningful impact.
Chris Mitton, President of Pearsanta further Opined: "
"This marks a transformative milestone for Pearsanta as we seek to revolutionize early cancer detection. With more than 50% of cancers still diagnosed at late stages—drastically reducing survival rates—we believe that there is a critical need for earlier and more accurate diagnostics. By securing a strong banking team and working
alongside experienced advisors, we are seeking to position Pearsanta to accelerate the commercialization of its technologies. Our mission is to expand access to innovative, non-invasive diagnostics that have the potential to improve outcomes for millions of patients worldwide."
Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt stated:
"Cancer remains to be one of humanities biggest health challenges. Pearsanta’s launch of its Mitomic® Technology platform
for the early detection of cancer, reflects our commitment to identifying, developing and accelerating some of the most promising health innovations.
The Board’s authorization to explore this path is a key first step in positioning Pearsanta for a successful global
launch.”
Chris Mitton, President of Pearsanta Added:
"The proposed IPO marks a transformative moment for Pearsanta as we seek to bring our groundbreaking Mitomic® Technology platform to the global stage. We believe this milestone will enable us to accelerate the commercialization of our early cancer detection solutions, empowering clinicians with tools for earlier and more accurate diagnoses.
Our focus remains on addressing critical unmet needs in healthcare, and this step is intended to position us to make a meaningful impact in the fight against cancer worldwide.”
“The treatment of autoimmune diseases will see a fundamental change in the next few years, a paradigm shift, which has been awaited since the processes were understood by which immune tolerance normally is being maintained. Restoring immune tolerance will replace immunosuppressants in the treatment of autoimmune diseases, and insulin eventually will become a mere rescue medication in type 1 diabetes. With the recent deal between Roche/Genentech and Cour on autoimmune
treatments, the race is on and will be won by the drug which best fulfils three main criteria: safety, effectiveness, and durability of response. Adimune’s ADI-100 is well positioned in this competitive endeavor. We are one of the front runners because we believe our drug candidate will meet all three criteria in a perfect manner.”
Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt and
Co-CEO of Adimune, added:
“Adimune represents an opportunity for a fundamental shift in the way we treat autoimmunity where reliance on immunosuppressants could be reduced or eliminated. With the successful completion of ADI-100’s preclinical efficacy and safety study, Adimune is
closer to bringing this therapy to human trials advancing its mission of addressing autoimmune diseases as one of the most pressing health challenges we face.”
Dr. Don Cilla, President and CEO of Appili Commented:
"The alignment with Aditxt will facilitate our access to capital and activates promising opportunities for Appili across multiple fronts. Through Aditxt’s social incubator
platform, we can amplify our impact and reach in the infectious diseases and medical countermeasure landscape.”
“By leveraging Aditxt’s mission to “Make Promising Innovations Possible Together“, we aim to prepare ATI-1701 for IND submission, implement FDA’s agreed upon strategy
for ATI-1801, and enhance commercialization for LIKMEZ™ and capitalize on the strategic value of two potential PRV eligible programs.”
Why Aditxt Inc. (NASDAQ: ADTX) Could
Be the Next Big Biotech Play
Aditxt Inc. (NASDAQ: ADTX) is making waves in the biotech space with its disruptive approach to immune modulation and precision diagnostics. Unlike traditional biotech firms focused on symptom management, Aditxt is pioneering immune
system monitoring and modulation, aiming to transform how autoimmune diseases, organ transplantation, and early disease detection are approached.
At the heart of Aditxt’s innovation is its multi-platform strategy, leveraging cutting-edge biotechnology to enhance immune health, improve diagnostic accuracy, and expand access to
neurological and infectious disease solutions. Through its three core subsidiaries—Adimune, Pearsanta, and Adivue—Aditxt is positioning itself as a key player in multiple high-growth healthcare markets.
Adimune – Redefining Immune Tolerance
Aditxt’s Adimune division is tackling one of the biggest challenges in immunology: the need for long-term immunosuppression in
organ transplantation and autoimmune disease treatment. Conventional therapies suppress the immune system, leading to severe side effects and limited efficacy. Adimune’s approach seeks to restore immune tolerance naturally, reducing dependency on immunosuppressants and revolutionizing long-term treatment strategies. This breakthrough has the potential to significantly enhance quality of life for patients with autoimmune diseases such as Type 1 diabetes, multiple sclerosis, and psoriasis.
Pearsanta – Precision Diagnostics for Early
Disease Detection
The biotech industry is shifting towards preventative healthcare, and Aditxt is at the forefront with Pearsanta, its precision diagnostics subsidiary. With late-stage cancer diagnoses leading to higher mortality rates and increasing healthcare costs, Pearsanta’s technology aims to enable early disease detection, improve prognosis monitoring, and ultimately enhance long-term health outcomes.
By leveraging advanced diagnostic tools, Pearsanta could play a pivotal role in the future of personalized medicine.
Adivue – Revolutionizing Brain Health with Neurodiagnostics
Aditxt’s Adivue platform is dedicated to neurodiagnostics and predictive technology, aiming to revolutionize cognitive health assessments. The company is focused on early identification of neurological disorders, including Alzheimer’s and other neurodegenerative diseases, through innovative diagnostic tools. Adivue’s
technology integrates EEG data acquisition, MRI imaging, and cloud-based telehealth services, creating a centralized hub for precision brain health diagnostics. With a rapidly growing market for neurological disease detection, Adivue’s solutions could prove invaluable in expanding access to decentralized, early-stage diagnostics.
Aditxt Inc. is vigorously expanding her ecosystem through strategic acquisitions and innovations. Two notable targets include:
Appili Therapeutics, a commercial-stage biopharma company focusing on infectious disease solutions,
including FDA-approved antimicrobial therapies and vaccines targeting biological threats.
Evofem, a biopharma innovator addressing unmet needs in women’s health, including non-hormonal contraceptive solutions. By integrating these acquisitions into its portfolio, Aditxt is diversifying its biotech footprint across immune health, diagnostics, neurological treatments, and infectious disease solutions—creating multiple revenue streams in high-demand sectors.
Why Aditxt Could Be a Game-Changer
Aditxt operates under a social innovation platform model, fostering collaboration between research institutions, industry partners, and shareholders to accelerate innovation. This ecosystem-driven approach democratizes biotech advancements, ensuring that cutting-edge health
solutions reach the market efficiently.
Moreover, Aditxt is currently trading with an intraday market cap of just $5.988 million, making it a highly speculative yet potentially explosive biotech play. The stock has been trading within a steep falling wedge pattern, and technical indicators suggest that a breakout above the
38.2% Fibonacci retracement level could trigger a massive surge—potentially up to 3,000% in the coming weeks.
With increasing volume, a disruptive biotech model, and multiple high-impact subsidiaries, Aditxt Inc. (NASDAQ: ADTX) is positioning itself as a high-risk, high-reward biotech stock to watch.
Under the leadership of CEO Amro Albanna, Aditxt Inc. (NASDAQ: ADTX) is emerging as a biotech innovator with a mission to transform immune health and precision diagnostics. By leveraging a multi-platform strategy that integrates immune modulation, early disease detection, and
neurodiagnostics, Aditxt is at the forefront of next-generation healthcare solutions. With a strong focus on disruptive innovation, strategic acquisitions, and scalable technology, ADTX is not just another biotech company—it’s a driving force in the future of personalized medicine and immune system optimization.
Growing Demand for Cancer Treatments Amid Rising Cases
The global cancer diagnostics market is experiencing rapid growth, driven by the increasing burden of cancer worldwide. According to the World Health Organization (WHO), new cancer cases are expected to reach 35 million by 2050, marking a staggering 77% increase from 2022. This rise in cases has heightened the demand for early and accurate diagnostics, as timely detection is critical for effective treatment and improved survival rates.
With advancements in diagnostic techniques such as immunohistochemistry, molecular
diagnostics, and next-generation sequencing, healthcare providers are now better equipped to identify cancer at earlier stages. Companies are heavily investing in research and development, as seen in partnerships like that of F. Hoffmann-La Roche and Janssen Biotech, which focus on enhancing diagnostic tools. The push for innovation is not only making cancer detection more precise but also enabling personalized treatment approaches, a major breakthrough in oncology.
Governments and healthcare organizations are also playing a crucial role in expanding cancer awareness and screening programs. Initiatives such as the Global Strategy for Cervical Cancer Elimination and colorectal cancer screening programs in the U.S. and U.K. highlight the global effort to encourage early detection. These programs are expected to
further drive the adoption of advanced diagnostic solutions, ultimately fueling the demand for improved cancer treatments.
Despite the growing need, challenges persist. High costs associated with diagnostics, limited access to advanced technologies in emerging markets, and supply chain disruptions continue to hinder widespread adoption. However, the expansion of telemedicine and online diagnostic tools is bridging gaps in accessibility, particularly in underserved regions. The
ongoing push for technological advancements, including AI-powered diagnostics and liquid biopsies, suggests that the market will continue to evolve, making cancer treatment more efficient and widely available in the years to come.
Technical Overview
Aditxt Inc. (NASDAQ: ADTX) shares have seen a 12.95% decline in the past 24 hours, currently trading within a steep falling wedge pattern—a historically bullish structure that often precedes explosive breakouts. This wedge has been forming since August 2023, signaling a prolonged consolidation phase. With the 24 hour Relative Strength Index (RSI) at 33.95, ADTX is in deeply
oversold territory, making it an attractive setup for a significant reversal.
The support level has already been established, preventing further downside pressure. If ADTX breaks above the 38.2% Fibonacci retracement level, it could act as the catalyst for a 3,000% surge, as traders recognize the wedge breakout and align with the strengthening biotech sector trend.
Despite being listed on NASDAQ, ADTX has an intraday market cap of just $5.988 million, an unusually low valuation given its positioning. This makes it a prime candidate for a revaluation, especially as trading volume continues to rise, indicating increased interest from buyers.
Further reinforcing the bullish thesis is the fact that ADTX is trading below the 50-day, 100-day,
and 200-day moving averages. Historically, when a stock is far below these levels with growing volume, it often signals a reversal is on the horizon. The combination of a tight trading range, declining seller pressure, and increasing accumulation suggests that ADTX is nearing a breakout point, with technical conditions aligning for a massive upward move.
Aditxt Inc. (NASDAQ: ADTX)- Key Metrics
Total Valuation -
Intraday Market Cap: $5.988M - Enterprise Value $11.23M
Aditxt Inc. (NASDAQ: ADTX) has a market cap or net worth of $5.988 million as of February 26, 2025. The next estimated earnings date is Tuesday, April 15, 2025, after market close.
Analyst Ratings
Mitchell Kapoor from HC Wainwright & Co. maintains a Strong Buy rating, raising the price target from $160 to $2,440, representing a staggering +2,843,722.84% potential upside since September 6, 2023.
Meanwhile, Jason Kolbert from Dawson James has downgraded his rating from Strong Buy to Hold, signaling a more cautious outlook on the
stock.
Why Now is the Time to Consider Aditxt, Inc. (NASDAQ: ADTX)
Aditxt, Inc. (ADTX) is trading at a valuation that suggests significant upside potential, with both market signals and company developments aligning for a possible breakout. The company is at the forefront of immune system reprogramming, developing cutting-edge solutions for organ transplant rejection, autoimmune diseases, and infectious disease monitoring. As the demand for precision medicine and immune diagnostics grows, Aditxt is strategically
positioned to capitalize on this expanding market.
The stock has seen a 12.96% decline in the past 24 hours, currently trading within a steep falling wedge pattern—a structure that often precedes explosive upward moves. This wedge has been forming since August 2023, indicating a prolonged consolidation phase. With RSI at 33,
ADTX is now deeply oversold, making it an attractive setup for a sharp reversal as selling pressure dissipates.
A critical support level has already been established, preventing further downside pressure. If ADTX breaks above the 38.2% Fibonacci retracement level, it could trigger a massive 3,000% surge, as traders recognize
the wedge breakout and align with the strengthening biotech sector trend.
With momentum building and conditions aligning for a major move, Aditxt, Inc. (NASDAQ: ADTX) could be one of
the most undervalued opportunities on the market right now.
Don’t miss out—this could be the moment before ADTX experiences a massive breakout.
As always, we
encourage you to conduct your own research and consider how Aditxt, Inc. (NASDAQ: ADTX) fits into your broader investment strategy.
This newsletter is a Paid Advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by DEXWireNews LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to DEXWireNews LLC.
You are reading this
newsletter because you have subscribed via our opt-In signup form on our website. If you have been subscribed by accident, then you may unsubscribe by clicking the link below.
By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or
licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research
and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our
website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be
based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here: We do NOT own shares of any of the companies mentioned herewithin, nor intend to buy any in the future.
You should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at http://www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud
at https://www.sec.gov/reportspubs/investor-publications/investorpubscyberfraudhtm.html, as well as related information published on how to invest carefully. You are responsible for verifying all claims and conducting your own
due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or
information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory
service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.
Our business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars electronically via bank wire by
One Eyed Jack Enterprises LLC for an advertising / marketing campaign for Aditxt, Inc. (NASDAQ: $ADTX) beginning on 2/24/2025 and ending on 3/5/2025. DEXWireNews may receive additional campaigns in the future by One Eyed Jack Enterprises LLC to distribute media for Aditxt, Inc. (NASDAQ: $ADTX).
Any compensation is a major conflict
of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our
database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements,
which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is
not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, we often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before
publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without
notice.
Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that
are minutes, hours, days or even weeks apart.
How is a potential investor impacted if they receive the Information later than other investors? If the trading volume and price of a Profile Issuer’s securities increases after the Information is provided to an earlier group of investors, then subsequent investors will pay inflated prices for any securities of the Profiled Issuers that they purchase. This will likely result in the Profiled Issuers having trading losses.
